• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 8th March 2021

International Women’s Day: Why We #Choosetochallenge

On International Women’s Day, OHE recognises the ongoing need to call out gender inequality, celebrates the achievements made in the health economics community, and reflects on why gender diversity is a ‘no-brainer’ for us as an organisation.

Lotte 2
Lotte Steuten
Pat-1-scaled-1
Patricia Cubi-Molla
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Wouldn’t this be a fantastic world if the International Women’s Day (IWD) did not exist? Or, better phrased, if the IWD did not have to exist. If that world would be a world where being a woman would not entail having fewer chances or being treated unequally. Oh, what a wonderful world this would be.

Yet, even in a world-class economy such as the UK, even in the XXI century, being a woman still comes with a number of disadvantages. For example: same work with lower salary; increasingly under-represented when moving up the stages of an academic career; gender bias in teaching evaluations; unequal share of household chores; and the highest uptake of home schooling in lockdown during the Covid-19 pandemic. As tough as it sounds, the United Nations reminds us that despite the world having made unprecedented advances, no country has achieved gender equality. As such, the International Women’s Day is a global day to celebrate all the achievements of women, in every dimension: social, economic, cultural and political; and it is also a day to reflect on the existing (sometimes invisible) barriers, and call for change.

Through this blog we want to reflect on the achievements of women in the landscape of Health Economics and Outcomes Research (HEOR); and call for change in the areas where inequalities still exist. We illustrate this with data on gender diversity among speakers at well-known HEOR associations: the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and the Health Economist’s Study Group (HESG), the main health economics association in the UK.

ISPOR’s ‘Women in HEOR initiative’ provides an insight in their journey towards gender diversity (we invite you to visit their slides as presented at ISPOR Europe 2019). In that session, Nancy S. Berg (CEO and Executive Director of ISPOR) showed that of all plenary speakers at ISPOR Conferences the percentage women increased from 26% in 2016 to 42% in 2019.  Similarly, good progress had also been achieved among programme committee members, up from 23% women in 2016 to 53% in 2019. The most positive piece of news perhaps is related to panel gender diversity. In 2019, all accepted panels were gender diverse. Among abstracts submitted, 11% were men-only (‘manels’), and 2% women-only (yeah, that exists).

Source: slides from ISPOR Forum ‘Women in HEOR initiative’ (ISPOR Europe 2019)

While we do not have exact data on the gender diversity of its members, the HEOR field in general does not strike us as particularly men-dominated, in terms of the relative proportion men and women working in this field. So, encouraging as they are, these results may still reflect some under-representation of women presenting their work at conferences. In perspective however, the results are not that bad: another report analysed events across 23 countries over a 5-year period (2013-2018) and found the uncomfortable truth that, of more than 60,000 event speakers, less than one-third were women (about one-fourth in the UK, we’re afraid). To further improve this, event organisers should ‘mind the gap’, while women should be encouraged to present their work and be a leader as much as men are. While this may sound like a daunting task given where we are today, HESG shows that achieving good representation of women is very well possible even at the highest ranks, with 54% of Heads of Health Economics Units in HESG identifying as women (boosting the UK’s gender diversity reputation in one go, thank you very much!).

International Women’s Day also calls for a shout out to all the great men out there, our allies, who actively advocate for and support gender diversity (and other types of diversity for matter). These are smart men too, as they understand that all of us, regardless of gender, will be better off with more diversity. Also, we would not be economists if we did not point out that, aside from gender equality being a value in and off itself, there is also a diversity dividend to gain from it. Diversity has been shown to significantly improve financial performance on measures such as profitable investments and overall returns. How so? Diverse teams make better decisions. As an organisation that exists to inform better decision- and policy-making in health, what could be more important?

Finally, though, a confession: at OHE, gender diversity is not actually top of mind every single day. The reason? It does not have to be. Mostly, gender equality seems a given to us, as it is ingrained in our organisational culture. Across the team, across roles and in the management team, women are equally represented if not outnumbering men. Pay is equal and career chances are too. Today at International Women’s Day, the OHE team celebrate this feat and realise to never take it for granted. We, still, are the exception, not the norm.

Related Insights

_DSC0175
  • Insight
  • September 2023

The Economics of Health in a Shifting Climate: Insights from the 2023 Annual Lecture

Read more
HTA Slovak Republic-1
  • Insight
  • September 2023

Around The World in HTAs: The Slovak Republic – Valuing the Future

Read more
Beige Minimalist Timeline Diagram Graph
  • Insight
  • August 2023

The changing role of the NHS over time

Read more
this one
  • Insight
  • July 2023

Around The World in HTAs: Egypt – The Road Ahead

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!